mental and behavioural disorder due to use of amphetamine相关文献:
The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.
JAMA Netw Open. 2025 May 1;8(5):e259492. doi: 10.1001/jamanetworkopen.2025.9492.
PMID:40343695
Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
Castells X, Blanco-Silvente L, Cunill R.
Cochrane Database Syst Rev. 2018 Aug 9;8(8):CD007813. doi: 10.1002/14651858.CD007813.pub3.
PMID:30091808
Binge Eating Disorder.
Guerdjikova AI, Mori N, Casuto LS, McElroy SL.
Psychiatr Clin North Am. 2017 Jun;40(2):255-266. doi: 10.1016/j.psc.2017.01.003. Epub 2017 Mar 6.
PMID:28477651
Psychostimulants in psychiatry.
Warneke L.
Can J Psychiatry. 1990 Feb;35(1):3-10. doi: 10.1177/070674379003500102.
PMID:2180548
Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes.
Taipale H, Bergström J, Gèmes K, Tanskanen A, Ekselius L, Mittendorfer-Rutz E, Helgesson M.
JAMA Netw Open. 2024 Mar 4;7(3):e242859. doi: 10.1001/jamanetworkopen.2024.2859.
PMID:38506810
Comparison of serious adverse effects of methylphenidate, atomoxetine and amphetamine in the treatment of ADHD: an adverse event analysis based on the FAERS database.
Wu L, Zhao D, Lan Y, Jin L, Yang L.
BMC Pharmacol Toxicol. 2025 Feb 20;26(1):38. doi: 10.1186/s40360-025-00868-5.
PMID:39980035
Captagone & Morbid Jealousy.
Shalaby AS, Badr Nassar OM, Bahanan AO, Alshehri MH, Nasr Abou Elzahab NF.
Psychopharmacol Bull. 2023 Feb 28;53(1):39-45.
PMID:36873918
Global prevalence of cannabis and amphetamine/methamphetamine use among adolescents in 47 countries: a population-based study from WHO database.
Son Y, Hong S, Yim Y, Kim S, Lee H, Lee K, Kim HJ, Jo H, Park J, Oh J, Lee S, Lee H, Nehs CJ, Smith L, Yon DK, Kang J.
World J Pediatr. 2025 Mar;21(3):291-305. doi: 10.1007/s12519-025-00883-w. Epub 2025 Mar 20.